Scutellarin, a bioactive component of flavonoid glycoside, is adopted for the treatment of apoplexy sequel, coronary artery disease and angina pectoris in clinic, which is a potent medicine for the treatment of heart vascular disease in aged people. However, scutellarin exhibits short biological half-life, quick elimination and low oral bioavailability, which restrict its application in clinic. The transdermal delivery system could overcome the disadvantage of these traditional dosage forms.
This paper ...